CureVac disappoints in COVID vaccine trial
Nature Podcast
00:00
Curvac Unmodified Vaccines
The company has said that they're going to finish the trial, because this was all based on an interm analysis of a hundred and 34 cases in a massive forty thousand person trial. In rat and monkey studies at least, it does look to be far better at eliciting antibodies. I think there's some people taking victory laps for modified arene and that that strategy has ultimately prevailed.
Transcript
Play full episode
